Whole Genome Non-invasive Prenatal Testing in Prenatal Screening Algorithm: Clinical Experience from 12,700 Pregnancies

Overview

Journal BMC Pregnancy Childbirth

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2022 Aug 9

PMID 35945516

Authors

Elena E Baranova

Olesya V Sagaydak

Alexandra M Galaktionova

Ekaterina S Kuznetsova

Madina T Kaplanova

Maria V Makarova

Maxim S Belenikin

Anton S Olenev

Ekaterina N Songolova

Affiliations

Soon will be listed here.

Abstract

Background: A fast adoption of a non-invasive prenatal testing (NIPT) in clinical practice is a global tendency last years. Firstly, in Russia according a new regulation it was possible to perform a widescale testing of pregnant women in chromosomal abnormality risk. The aim of the study-to assess efficiency of using NIPT as a second-line first trimester screening test in Moscow.

Methods: Based on the first trimester combined prenatal screening results 12,700 pregnant women were classified as a high-risk (cut-off ≥ 1:100) and an intermediate-risk (cut-off 1:101 - 1:2500) groups followed by whole genome NIPT. Women from high-risk group and those who had positive NIPT results from intermediate-risk group were considered for invasive prenatal diagnostic.

Results: 258 (2.0%) samples with positive NIPT results were detected including 126 cases of trisomy 21 (T21), 40 cases of T18, 12 cases of T13, 41 cases of sex chromosome aneuploidies (SCAs) and 39 cases of rare autosomal aneuploidies (RAAs) and significant copy number variations (CNVs). Statistically significant associations (p < 0.05) were revealed for fetal fraction (FF) and both for some patient's (body mass index and weight) and fetus's (sex and high risk of aneuploidies) characteristics. NIPT showed as a high sensitivity as specificity for common trisomies and SCAs with an overall false positive rate 0.3%.

Conclusions: NIPT demonstrated high sensitivity and specificity. As a second-line screening test it has shown a high efficiency in detecting fetus chromosomal anomalies as well as it could potentially lower the number of invasive procedures in pregnant women.

Citing Articles

A Decade of Non-Invasive Prenatal Testing (NIPT) for Chromosomal Abnormalities in Croatia: First National Monocentric Study to Inform Country's Future Prenatal Care Strategy.

Podobnik P, Mestrovic T, dordevic A, Kurdija K, Jelcic D, Ogrin N Genes (Basel). 2025; 15(12.

PMID: 39766857 PMC: 11675109. DOI: 10.3390/genes15121590.

Approach and Management of Pregnancies with Risk Identified by Non-Invasive Prenatal Testing.

Gug M, Ratiu A, Andreescu N, Farcas S, Laitin S, Gug C J Pers Med. 2024; 14(4).

PMID: 38672993 PMC: 11050912. DOI: 10.3390/jpm14040366.

Cell-Free Fetal DNA Screening Analysis in Korean Pregnant Women: Six Years of Experience and a Retrospective Study of 9327 Patients Analyzed from 2017 to 2022.

Park J, Kang K, Kim H, Jang H, Go M, Yang S J Pers Med. 2023; 13(10).

PMID: 37888079 PMC: 10608624. DOI: 10.3390/jpm13101468.

Application of non-invasive prenatal testing to 91,280 spontaneous pregnancies and 3477 pregnancies conceived by in vitro fertilization.

Wei R, Li J, Xia Y, Wang C, Lu X, Fang Y Mol Cytogenet. 2023; 16(1):25.

PMID: 37726793 PMC: 10507956. DOI: 10.1186/s13039-023-00656-y.

Non-Invasive Prenatal Testing (NIPT): Reliability, Challenges, and Future Directions.

Jayashankar S, Nasaruddin M, Hassan M, Dasrilsyah R, Shafiee M, Ismail N Diagnostics (Basel). 2023; 13(15).

PMID: 37568933 PMC: 10417786. DOI: 10.3390/diagnostics13152570.

References

Hui L, Bianchi D . Fetal fraction and noninvasive prenatal testing: What clinicians need to know. Prenat Diagn. 2019; 40(2):155-163. PMC: 10040212. DOI: 10.1002/pd.5620. View

Pos O, Budis J, Szemes T . Recent trends in prenatal genetic screening and testing. F1000Res. 2019; 8. PMC: 6545823. DOI: 10.12688/f1000research.16837.1. View

Lau T, Chan M, Lo P, Chan H, Chan W, Koo T . Clinical utility of noninvasive fetal trisomy (NIFTY) test--early experience. J Matern Fetal Neonatal Med. 2012; 25(10):1856-9. PMC: 3483059. DOI: 10.3109/14767058.2012.678442. View

MacDorman M . Race and ethnic disparities in fetal mortality, preterm birth, and infant mortality in the United States: an overview. Semin Perinatol. 2011; 35(4):200-8. DOI: 10.1053/j.semperi.2011.02.017. View

Palomaki G, Kloza E . Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing. Genet Med. 2018; 20(11):1312-1323. DOI: 10.1038/gim.2018.22. View

Kanmaz A, Inan A, Beyan E, Ogur S, Budak A . Effect of advanced maternal age on pregnancy outcomes: a single-centre data from a tertiary healthcare hospital. J Obstet Gynaecol. 2019; 39(8):1104-1111. DOI: 10.1080/01443615.2019.1606172. View

Benn P, Cuckle H, Pergament E . Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 2013; 42(1):15-33. DOI: 10.1002/uog.12513. View

Neofytou M . Predicting fetoplacental mosaicism during cfDNA-based NIPT. Curr Opin Obstet Gynecol. 2020; 32(2):152-158. DOI: 10.1097/GCO.0000000000000610. View

Goldenberg P . An Update on Common Chromosome Microdeletion and Microduplication Syndromes. Pediatr Ann. 2018; 47(5):e198-e203. DOI: 10.3928/19382359-20180419-01. View

10.

Baranov A, Namazova-Baranova L, Belyaeva I, Bombardirova E, Smirnov I . [Medical and Social Problems of Assisted Reproductive Technologies from the Perspective of Pediatrics]. Vestn Ross Akad Med Nauk. 2015; (3):307-14. DOI: 10.15690/vramn.v70i3.1326. View

11.

Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, Zhu Z . Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol. 2015; 45(5):530-8. DOI: 10.1002/uog.14792. View

12.

Wang Y, Li S, Wang W, Dong Y, Zhang M, Wang X . Cell-free DNA screening for sex chromosome aneuploidies by non-invasive prenatal testing in maternal plasma. Mol Cytogenet. 2020; 13:10. PMC: 7068885. DOI: 10.1186/s13039-020-0478-5. View

13.

Ramdaney A, Hoskovec J, Harkenrider J, Soto E, Murphy L . Clinical experience with sex chromosome aneuploidies detected by noninvasive prenatal testing (NIPT): Accuracy and patient decision-making. Prenat Diagn. 2018; 38(11):841-848. DOI: 10.1002/pd.5339. View

14.

Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A . Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013; 33(7):662-6. DOI: 10.1002/pd.4119. View

15.

Livergood M, LeChien K, Trudell A . Obesity and cell-free DNA "no calls": is there an optimal gestational age at time of sampling?. Am J Obstet Gynecol. 2017; 216(4):413.e1-413.e9. DOI: 10.1016/j.ajog.2017.01.011. View

16.

Liu H, Gao Y, Hu Z, Lin L, Yin X, Wang J . Performance Evaluation of NIPT in Detection of Chromosomal Copy Number Variants Using Low-Coverage Whole-Genome Sequencing of Plasma DNA. PLoS One. 2016; 11(7):e0159233. PMC: 4945049. DOI: 10.1371/journal.pone.0159233. View

17.

Ashoor G, Syngelaki A, Poon L, Rezende J, Nicolaides K . Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2012; 41(1):26-32. DOI: 10.1002/uog.12331. View

18.

Qiao L, Zhang Q, Liang Y, Gao A, Ding Y, Zhao N . Sequencing of short cfDNA fragments in NIPT improves fetal fraction with higher maternal BMI and early gestational age. Am J Transl Res. 2019; 11(7):4450-4459. PMC: 6684886. View

19.

Taylor-Phillips S, Freeman K, Geppert J, Agbebiyi A, Uthman O, Madan J . Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open. 2016; 6(1):e010002. PMC: 4735304. DOI: 10.1136/bmjopen-2015-010002. View

20.

Porreco R, Garite T, Maurel K, Marusiak B, Ehrich M, Van Den Boom D . Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol. 2014; 211(4):365.e1-12. DOI: 10.1016/j.ajog.2014.03.042. View